top of page
Click here for Product Demo
Video
Clinical Validations
Click each link below for full clinical/validation published studies

Validations and Clinical Studies

Concussion/TBI –Neurological (Alzheimer’s Parkinson’s 140 other Neurodegenerative).
 

National Library of Medicine- National Center for biotechnology Information J Alzheimers Dis.2022;86(3):1275-1285.

 doi: 10.3233/JAD-210636.

•

1.Olfactory Dysfunction in Neurodegenerative Diseases.Marin C, Vilas D, Langdon C, Alobid I, López-Chacón M, Haehner A, Hummel T, Mullol J.

​

2.Olfaction as an early marker of Parkinson's disease and Alzheimer's disease.Walker IM, Fullard ME, Morley JF, Duda JE.Handb Clin Neurol. 2021;182:317-329. doi: 10.1016/B978-0-12-819973-2.00030-7.PMID: 34266602

​

3.Olfactory,Concussion, cognitive and affective dysfunction assessed 24 hours and one year after a mild Traumatic Brain Injury (mTBI)

​

4.Traumatic brain injury and olfaction: a systematic review

​

5.Increases of phospho-Tau (Ser202/Thr205) in the olfactory regions are associated with impaired EEG and olfactory behavior in traumatic brain injury mice


6. 1  Clinical validation of an open-access SARS-COV-2 antigen detection lateral flow            assay, compared to commercially available assays

​

7.The usefulness of a quantitative olfactory test for the detection of COVID-19.

    World’s leading institutes in Studies of Infections Disease and Public Health)

​

8.Modeling the effectiveness of olfactory testing to limit SARS-CoV-2 transmission

​

MSP 5 Scent odorant Olfactory Test validations.

5 scent odorant in multiple clinical studies including:

•FDA Medical Device Registration validation.

•MSP exceeds minima odorant detection requirements.

     1 Institute of Clinical Pharmacology, Goethe –Oxford

•Odorant Testing Requirements protocol. St Croix Sensory Inc.

Due to the sensitive in nature product, protection of intellectual property, additional MSP Validations Pack may be provided upon request. 

​

9. •Smell loss may precede a Parkinson's diagnosis by up to 10 years. Lasting smell loss can be a risk factor for brain disease. PPMI Clinical Study

​

10. 644 associated clinical studies-Olfactory disorder Parkinson's disease NIH NLOM Clinical PMC

Olfaction Disorder and Alzheimer's Disease Studies

​

11. •Olfaction as an early marker of Parkinson's disease and Alzheimer's /pubmed.ncbi.nlm.nih.gov/34266602/

​

12. •Loss of smell linked to Alzheimer’s cognitive impairment and biomarkers. NIH Link to Clinical Studies

Olfaction Disorder and Viral Infection

​

13. •The overwhelming majority—approximately 86% of people—who have COVID-19 report either partial or total loss of their ability to smell.

​

14. Olfaction Disorder and Concussion

•“It's long been known that people who suffer a major concussion can lose their sense of smell temporarily” Sciencedaily.com

​

15. Olfactory, cognitive and affective dysfunction assessed 24 hours and one year after a mild Traumatic Brain Injury (mTBI)

 

16. developments have led to the proliferation of standardized olfactory testing in laboratories and clinics, and to the discovery that smell loss is among the first signs of a number of neurodegenerative diseases, including Alzheimer's disease and idiopathic Parkinson's disease.  https://pubmed.ncbi.nlm.nih.gov/11148312/

bottom of page